Letter by Giral et al regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)"

Circulation. 2014 Oct 21;130(17):e151. doi: 10.1161/CIRCULATIONAHA.114.009590.

¹ Institut E3M, Pole Coeur et Métabolisme, Groupe Hospitalier Pitié Salpétrière, AP/HP, Paris FranceInstitute for Cardiovascular, Metabolic, and Nutritional Diseases and UMRS 1166, National Institute for Health and Medical Research (INSERM) and Pierre et Marie Curie University, Paris, France.
² Institute for Cardiovascular, Metabolic and Nutritional Diseases, National Institute for Health and Medical Research (INSERM) and Pierre et Marie Curie University, Paris, France.
³ Institute for Cardiovascular, Metabolic, and Nutritional Diseases and UMRS 1166, National Institute for Health and Medical Research (INSERM) and Pierre et Marie Curie University, Paris, France.

No abstract available

Publication types